Atara Biotherapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Atara Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $13.67. The average 1-year stock price forecast is 28.84% higher than the current stock price, while the lowest is $10 (-5.75%) and the highest is $18 (+69.65%).

Price Target: $13.67 (+28.84%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$10	$13.67	$13	$18
Change	-5.75%	+28.84%	+22.53%	+69.65%

* Price targets were last updated on May 18, 2026.

Analyst Ratings

The average analyst rating for Atara Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	May '26
Strong Buy	4	4	2	2	2	3
Buy	0	0	0	0	0	0
Hold	1	1	2	2	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	1	1	1	0
Total	5	5	5	5	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ilya Zubkov Freedom Capital Markets	Freedom Capital Markets	Hold Upgrades $4 → $10	Hold	Upgrades	$4 → $10	-5.75%	May 18, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $13	Buy	Maintains	$13	+22.53%	May 13, 2026
Salim Syed Mizuho Securities	Mizuho Securities	Buy Maintains $18	Buy	Maintains	$18	+69.65%	Mar 30, 2026

Financial Forecast

Revenue This Year

2.11M

from 120.77M

-98.26%

from 120.77M

Revenue Next Year

45.08M

from 2.11M

2,040.99%

from 2.11M

EPS This Year

-0.88

from 2.57

EPS Next Year

1.27

from -0.88

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	20.34M	63.57M	8.57M	128.94M	120.77M	2.11M
Revenue Growth	-	212.55%	-86.52%	1,404.02%	-6.34%	-98.26%
Gross Profit	-261.66M	-206.42M	-219.48M	-26.34M	74.62M	1.45M
Gross Margin	-1,286.44%	-324.69%	-2,560.12%	-20.43%	61.79%	69.00%
Operating Income	-340.46M	-274.55M	-269.28M	-78.33M	49.47M	-13.43M
Net Income	-340.14M	-228.30M	-276.13M	-85.40M	32.69M	-13.19M
EPS	-	-	-	-	2.57	-0.88
Free Cash Flow	-128.98M	-192.99M	-55.72M	-1.68M	-47.68M	-3.00M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	5.0M
Avg	2.1M
Low	516,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	-95.9%
Avg	-98.3%
Low	-99.6%

EPS Forecast

EPS	2026	2027	2028
High	-0.53
Avg	-0.88
Low	-1.23

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-